Stay updated on Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial

Sign up to get notified when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.0%
    Check dated 2025-02-03T08:45:37.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.0%
    Check dated 2025-01-19T22:43:11.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.1%
    Check dated 2025-01-12T18:13:24.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The European Myeloma Network has added new results related to Velcade, including updated definitions and metrics for progression-free survival (PFS), overall response rates (ORR), and MRD negativity rates, with a maximum follow-up time of 54.41 months, while previous entries regarding post-consolidation MRD negativity and various timelines for response assessments have been removed.
    Difference
    28%
    Check dated 2024-12-29T07:49:03.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The website has been updated from version 2.13.2 to 2.13.3.
    Difference
    0.0%
    Check dated 2024-12-14T22:43:42.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.
    Difference
    1%
    Check dated 2024-12-07T16:17:53.000Z thumbnail image

Stay in the know with updates to Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.